Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
AN2 Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ANTX
Nasdaq
8731
https://www.an2therapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for AN2 Therapeutics Inc
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
- Mar 28th, 2024 8:10 pm
13 Best Falling Stocks To Buy Right Now
- Feb 22nd, 2024 9:21 am
UPDATE 1-AN2 Therapeutics to pause lung disease study enrollment
- Feb 12th, 2024 12:04 pm
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
- Feb 12th, 2024 11:45 am
We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
- Feb 1st, 2024 12:29 pm
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
- Jan 30th, 2024 9:10 pm
AN2 Therapeutics Inc Chief Strategy Officer Kevin Krause Sells 7,417 Shares
- Jan 12th, 2024 8:02 am
Recent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's Why
- Jan 10th, 2024 1:50 pm
One AN2 Therapeutics Insider Raised Their Stake In The Previous Year
- Nov 12th, 2023 12:06 pm
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
- Nov 9th, 2023 9:05 pm
AN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's Why
- Nov 6th, 2023 1:50 pm
AN2 Therapeutics to Present at Upcoming Investor Conferences
- Nov 6th, 2023 12:00 pm
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
- Oct 18th, 2023 11:00 am
AN2 Therapeutics, Inc. (NASDAQ:ANTX) stock most popular amongst individual investors who own 29%, while private equity firms hold 27%
- Oct 16th, 2023 10:43 am
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
- Oct 11th, 2023 4:01 am
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?
- Sep 27th, 2023 1:40 pm
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
- Sep 26th, 2023 11:00 am
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
- Sep 13th, 2023 11:00 am
Has AN2 Therapeutics (ANTX) Outpaced Other Medical Stocks This Year?
- Sep 11th, 2023 1:40 pm
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
- Aug 16th, 2023 2:42 am
Scroll